After receiving some positive commentary from an analyst, shares of TherapeuticsMD (NYSEMKT: TXMD), a drug maker focused on women’s health, rose 18% as of 11:00 a.m. EDT on Tuesday.
Shareholders can thank Jay Olson, an analyst at Oppenheimer, for today’s price action. Olson upgraded TherapeuticsMD stock from “Perform” to “Outperform” earlier today and gave shares a $10 price target. That target implies 100% upside from yesterday’s closing price of just over $5.